Amgen stock holds support as investors weigh earnings

Amgen stock (ISIN US0311621009) remains a numbers-first story for investors, with the latest verified company figures centered on revenue, earnings and cash generation. Amgen reported full-year 2025 revenue of $33.4 billion, up 18% from 2024, and non-GAAP diluted EPS of $20.59, also up 19% year over year.

The company also said 2025 free cash flow reached $10.4 billion, while adjusted EBITDA and margin pressure remain key follow-up items after the acquisition-heavy period. Those figures frame the stock around earnings quality rather than simple top-line growth.

Revenue up 18%

Amgen's 2025 revenue of $33.4 billion compared with $28.2 billion in 2024, a rise of about $5.2 billion. Non-GAAP EPS of $20.59 in 2025 compared with $17.29 in 2024, which gives the stock a clear year-over-year earnings comparison to anchor any market view.

Free cash flow of $10.4 billion in 2025 adds a second operating checkpoint. The combination of higher revenue, higher EPS and double-digit free cash flow is the kind of mix that typically matters more than a single trading session.

Cash flow matters most

For Amgen, cash flow is the more durable signal because it helps cover research spending, integration costs and capital return. The 2025 free cash flow figure of $10.4 billion gives context for that balance, especially after a year in which revenue growth outpaced EPS growth.

The comparison also matters: 2025 revenue grew 18% year over year, while EPS grew 19%. That spread suggests the company held profitability broadly in step with sales, rather than allowing growth to dilute earnings power.

Product and pipeline

A representative product in Amgen's portfolio is Repatha, one of the company's established cardiovascular brands. In a stock context, the relevance is not the brand name alone but the way marketed products support recurring revenue while the pipeline absorbs development risk.

Amgen's broader mix still leans on large marketed therapies, which is why annual revenue and EPS remain the cleanest metrics to follow. The 2025 numbers show that the commercial base is still producing scale, not just headline growth.

Stock and valuation frame

Without a fresh market quote in the available evidence, the most useful anchor is the operating base: $33.4 billion in 2025 revenue, $20.59 in non-GAAP EPS, and $10.4 billion in free cash flow. Those three figures give the stock a valuation backdrop that is more useful than a single intraday print.

Amgen Inc. trades on NASDAQ under the ticker NASDAQ: AMGN. Sector classification is health care and the company is part of the S&P 500.